| |
The significant scientific capabilities of local talent, infrastructure and the island's decades of expertise fuel CytoImmune's Puerto Rican clinical cell manufacturing facility’s success. Learn how your business can do the same.
|
|
Today’s Big NewsFeb 5, 2024 |
| By Eric Sagonowsky,Kevin Dunleavy,Angus Liu,Fraiser Kansteiner,Zoey Becker Last year, the value of the top 10 M&A deals in the biopharma industry came to $115.8 billion, outranking prior sums from 2022, 2021 and 2020, which came to $65 billion, $53 billion and $97 billion, respectively. This report breaks down the industry's 10 largest M&A agreements of the year. |
|
|
|
By Nick Paul Taylor Johnson & Johnson’s $6.5 billion autoimmune drug has hit the mark in a phase 3 trial. The success tees J&J up to talk to regulators about approving the anti-FcRn antibody in generalized myasthenia gravis (gMG), although questions about the competitiveness of the late-to-market asset remain unanswered. |
By Fraiser Kansteiner Late last month, Novo Holdings’ CEO Kasim Kutay hinted that the fund manager was eyeing buyouts as an outlet for its trove of Wegovy cash. Now, a major deal has materialized. |
By Andrea Park After losing a patent infringement lawsuit last year that ended with an order to pay out $31 million in damages, leaving it all but hanging by a thread, NanoString is plotting a new way forward. |
By James Waldron With the IPO window now firmly wedged open, Metagenomi is the latest biotech to set out expectations for going public—even if they are slightly more modest than peer companies have seen in recent weeks. |
By Conor Hale Presented as a late-breaking trial at the International AF Symposium in Boston, the single-arm study showed 75.6% of patients demonstrated no signs of atrial fibrillation recurrence as well as no evidence of other atrial arrhythmias, such as tachycardia or flutter. |
By Angus Liu After leading Swiss drug giants Novartis and Roche through pivotal years, their CEOs have each netted multimillion-dollar compensation packages for 2023. |
By Andrea Park An app developed by Cedars-Sinai for use with Apple’s new spatial computing headset is putting a new spin on the concept of virtual care. |
By Max Bayer The highest dose of Pliant's liver disease treatment passed a phase 2 data, showing that it was safe and tolerable. But exploratory efficacy failed to differentiate from lower doses. |
By Conor Hale The company’s series E round was led by Fannin Partners, alongside backing from previous investors such as Bluebird Ventures, and includes the conversion of $10 million in previous interim financing. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
